Aon is bringing solutions to the market that help companies avoid capital raises that can result in dilution of equity value. Aon's Intellectual Property (IP) Solutions team combined its proprietary IP valuation tools and a collateral protection insurance policy to help create an IP-collateralized debt structure that allowed BrainScope to raise additional funds without diluting the current equity value. IP and intangible assets now represent 90 percent of the value of Fortune 500 companies, but IP value is not widely understood in capital markets. Aon is working with companies like BrainScope to help them seek access to non-dilutive growth capital by valuing intangible assets and structuring capital solutions that leverage such value.
About BrainScope
BrainScope is a medical neurotechnology company that is improving brain health by providing objective, diagnostic insights that enable better patient care. BrainScope is leading the way in the rapid and objective assessment of brain-related conditions, starting with mild traumatic brain injury (mTBI), utilizing multiple integrated assessment capabilities, artificial intelligence (AI), and digitization. The company's technology supports the American College of Emergency Physicians (ACEP) Choosing Wisely® campaign to avoid CT scans of the head in emergency department patients with minor head injury. BrainScope's innovative EEG-based, AI-derived algorithms empower physicians to quickly make accurate head injury assessments, addressing the full spectrum of traumatic brain injuries from structural (brain bleed) to functional (concussion) injuries, providing for the first time a full picture of the injury, and doing so in less time and without radiation.
About Aon
Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Our colleagues provide our clients in over 120 countries with advice and solutions that give them the clarity and confidence to make better decisions to protect and grow their business.
Back to HCB News
